Drugs / lente
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01798706 Background | Jun 2013 → Feb 2015 | type 2 diabetes mellitus | Sanofi | Completed | Met primary |
| — | NCT01424046 Comparator | May 2011 → Jun 2014 | type 1 diabetes mellitus | University of Pittsburgh | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lente | “Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.” NCT01798706 ↗1“Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .” NCT01424046 ↗ |
| Modality | Protein / enzyme biologic | “Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .” NCT01424046 ↗ |